HomeCompareTLIS vs EQR

TLIS vs EQR: Dividend Comparison 2026

TLIS yields 70.42% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TLIS wins by $1.03M in total portfolio value
10 years
TLIS
TLIS
● Live price
70.42%
Share price
$2.84
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.07M
Annual income
$282,657.96
Full TLIS calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — TLIS vs EQR

📍 TLIS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTLISEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TLIS + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TLIS pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TLIS
Annual income on $10K today (after 15% tax)
$5,985.92/yr
After 10yr DRIP, annual income (after tax)
$240,259.27/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, TLIS beats the other by $237,012.60/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TLIS + EQR for your $10,000?

TLIS: 50%EQR: 50%
100% EQR50/50100% TLIS
Portfolio after 10yr
$556.3K
Annual income
$143,238.78/yr
Blended yield
25.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

TLIS
Analyst Ratings
1
Hold
3
Sell
Consensus: Sell
Altman Z
-12.3
Piotroski
1/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TLIS buys
0
EQR buys
0
No recent congressional trades found for TLIS or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTLISEQR
Forward yield70.42%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$1.07M$40.5K
Annual income after 10y$282,657.96$3,819.61
Total dividends collected$914.3K$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusSellHold

Year-by-year: TLIS vs EQR ($10,000, DRIP)

YearTLIS PortfolioTLIS Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$17,742$7,042.25$11,248$547.57+$6.5KTLIS
2$30,661$11,677.14$12,701$666.53+$18.0KTLIS
3$51,667$18,859.73$14,405$814.59+$37.3KTLIS
4$84,985$29,701.39$16,413$999.84+$68.6KTLIS
5$136,593$45,658.47$18,795$1,232.92+$117.8KTLIS
6$214,738$68,583.71$21,639$1,527.95+$193.1KTLIS
7$330,537$100,766.97$25,057$1,903.80+$305.5KTLIS
8$498,633$144,958.95$29,197$2,385.87+$469.4KTLIS
9$737,910$204,372.63$34,250$3,008.70+$703.7KTLIS
10$1,072,222$282,657.96$40,467$3,819.61+$1.03MTLIS

TLIS vs EQR: Complete Analysis 2026

TLISStock

Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.

Full TLIS Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this TLIS vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TLIS vs SCHDTLIS vs JEPITLIS vs OTLIS vs KOTLIS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.